Three potential takeover targets in psychedelics

Lilly’s recent deal to acquire AtaiBeckley gave the field a boost, but other biotechs still need to prove their clinical and commercial potential.

By Kelly Bilodeau • Aug. 4, 2026

The future of oral drug delivery must be sustainable

How Evonik is shaping more sustainable oral drug delivery through data and excipient innovation.

By Lucas Cusin, Global Technical Marketing Manager, Oral Drug Delivery Solutions, Evonik & Thilo Krapfl, Head of Product Line Oral Drug Delivery Solutions, Evonik • Aug. 3, 2026

Explore the Trendline➔

Artificial intelligence & machine learning

After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

By PharmaVoice staff

Genetic clues for cell therapy toxicities; Summit’s high-stakes FDA decision

Researchers have pinpointed genes linked to dangerous CAR-T cell therapy side effects, and a predictions market weighs in on Summit’s closely-watched cancer drug.

By PharmaVoice Staff • July 31, 2026

How Telix landed a $2.1 billion radiopharma deal with Regeneron

Regeneron tapped the Aussie biotech to enter the radiopharma market with a multi-pronged agreement. 

By Alexandra Pecci • July 30, 2026

BMS and Gilead rule in the CAR-T space. Off-the-shelf developers aren’t trying to change that.

Rather than going head-to-head with approved CAR-T cell therapies, biotechs like Caribou Biosciences are positioning their drugs to fill unique market gaps.

By Kelly Bilodeau • July 29, 2026

Kalshi is expanding online betting in drug R&D — unless detractors can stop it

Kalshi sees drug development predictions as a way to improve R&D transparency. Critics say they could create financial incentives around research and undermine public trust.

By Susanna Vogel • July 28, 2026

Why 3 secretive biotechs are keeping their science close to the chest

Startups like Altos Labs are keeping pipeline details scarce to protect their ideas from competitors — but some experts say stealth only works for biotechs with deep pockets.

By Kelly Bilodeau • July 27, 2026

Lilly’s leap into psychedelics; peptides in the spotlight

Eli Lilly is extending its push in neuroscience while the FDA wrestles with controversial peptide drugs. 

By PharmaVoice Staff • July 24, 2026

What’s in the FDA’s latest batch of rejection letters

A look at two recent CRLs demonstrate the tension and discrepancies between how companies and the agency communicate drug rejections.

By Alexandra Pecci • July 23, 2026

Biopharma challenges leaders want to tackle

Boosting public trust, delivering genuine breakthroughs and getting trials off the ground remain top-of-mind issues in the industry.

By Meagan Parrish • July 23, 2026

Beyond weight loss: Lilly aims for leadership in brain science

Lilly’s neuroscience chief discusses the large pharma’s aims in brain science, and how diagnostics and dosing are driving its next advancements in Alzheimer’s.

By Kelly Bilodeau • July 21, 2026

As the Ebola outbreak rages, new treatments are headed into trials. Will they work?

The strain causing the current outbreak has no approved treatments or vaccines but global organizations are rushing to change that.

By Alexandra Pecci • July 20, 2026

Long days, dinners with copious alcohol, and the hunt for emerging assets in China

Why building relationships, navigating cultural nuances and preparing for different deal structures are key to investing in China’s promising drugs.

By Meagan Parrish • July 17, 2026

This startup thinks humans in clinical trials could become a ‘formality’

Deep Origin is attempting to create “virtual humans” that could one day reduce late-stage safety failures and the need for animal testing.

By Alexandra Pecci • July 16, 2026

How well are AI-discovered drugs faring in the clinic?

Some of the industry’s most closely-watched AI drugs could provide insight into the success of technology-assisted development.

By Kelly Bilodeau • July 15, 2026

Galimedix is keeping the amyloid hypothesis alive

The right target but the wrong approach? Why Galimedix’s co-founder believes the company has found an edge in treating Alzheimer’s disease with an amyloid drug.

By Kelly Bilodeau • July 14, 2026

Biotech funding gap widens despite rebound in VC investment

Nearly 70 venture-backed biotech startups raised more than $9.1 billion between January and June, but the majority already had drugs in testing.

By Gwendolyn Wu • July 14, 2026

Moderna, Takeda and Capricor on the verge of notching big drug approvals

Two of the companies are taking a second-go at FDA approval this summer, while another hopes to cement its leader-status in the battle to bring a new sleep treatment to market.

By Alexandra Pecci • July 13, 2026

What pharma leaders wish they knew on day 1

PharmaVoice checked in with four life sciences executives after they landed a new role. Now they’re looking back on what they learned.

By Alexandra Pecci • July 9, 2026

HHS plan to speed drug R&D won’t remove ‘self-inflicted’ delays

U.S. clinical trials continue to lose ground to China, but is Operation Trialblazer enough to help America catch up?

By Kelly Bilodeau • July 8, 2026

Can anyone catch up to Eli Lilly?

While rivals scramble to replace lost revenue, Lilly is opening an unprecedented gap by being a “contrarian,” as one expert says.

By Kelly Bilodeau • July 7, 2026

Beyond Boston: Unlikely cities stake biotech claims

As Greater Boston’s biotech industry sheds jobs, three unlikely regions are showing promise as up-and-coming hubs.

By Alexandra Pecci • July 6, 2026

Doctor-turned-dealmaker reveals his M&A playbook

Dr. David Hung is pulling multiple financial levers to put Nuvation Bio on strong footing as it advances its oncology drugs.

By Kelly Bilodeau • July 1, 2026

These biotechs just landed big fundraising hauls. Here’s what they pitched to investors.

Biotechs aimed at eye diseases, autoimmune conditions and longevity medicine have pulled in some of the largest capital raises so far this year.

By Kelly Bilodeau • June 30, 2026

3 late-stage MASH drugs that could rival Rezdiffra

The red-hot market has plenty of room for additional therapies from big name players and clinical stage companies alike.

By Alexandra Pecci • June 29, 2026